In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is presenting Spring 2020 events through online platforms and some of our previously scheduled events are being postponed to a later date. Please check our events listing for the latest information and contact our Customer Service team with any additional questions. For Academy programs and resources about COVID-19, click here.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Bisphosphonates and Osteonecrosis of the Jaw

Edited by Edited by John P. Bilezikian and John T. Grbic (Columbia University College of Physicians and Surgeons, New York, New York)
Bisphosphonates and Osteonecrosis of the Jaw

Published: February 2011

Volume 1218

Learn More

\"Bisphosphonates and Osteonecrosis of the Jaw\" stems from a conference held at the New York Academy of Sciences organized by John P. Bilezikian and John T. Grbic (Columbia University College of Physicians and Surgeons, New York, New York), G. David Roodman (University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania), and Catherine H. Van Poznak (University of Michigan, Ann Arbor, Michigan). Bisphosphonates work by inhibiting osteoclast action. Millions of people with osteoporosis and other bone diseases have been treated with bisphosphonates. These drugs are also used in chemotherapy to prevent bone pain and bone loss in advanced cancer that has metastasized. In the past few years there have been reports that patients on bisphosphonates have been developing a condition termed osteonecrosis of the jaw (ONJ). The papers in this volume discuss various aspects of ONJ and strategies to move the research on bisphosphonates and ONJ forward, as well as evaluate the risk of ONJ relative to the beneficial effects of bisphosphonates.